Skip to main content
Fig. 9 | BMC Medical Genomics

Fig. 9

From: Construction and experimental validation of an acetylation-related gene signature to evaluate the recurrence and immunotherapeutic response in early-stage lung adenocarcinoma

Fig. 9

ARS served as a promising predictor for immunotherapeutic efficacy. A The association between ARS and the immune cell infiltration levels in the early-stage LUAD subjects from TCGA. B ARS was negatively associated with IPS. C and D The ARS levels among the responders and non-responders to ICIs in the GSE126044 cohort (C) and GSE135222 cohort (D). E ARS could distinguish the subjects with poor progression-free survival rates in the GSE135222 cohort. F ARS was superior to IPS to predict the anti-PD-1 treatment effectiveness in the GSE126044 cohort. G The combination of ARS and IPS could better evaluate the immunotherapeutic efficacy in the GSE126044 cohort. ARS acetylation-related score, LUAD lung adenocarcinoma, TCGA the Cancer Genome Atlas, IPS immunophenoscore, ICIs immune checkpoint inhibitors; **P < 0.01; ***P < 0.001

Back to article page

BMC Medical Genomics

ISSN: 1755-8794

Contact us